Rising Tide Foundation for Clinical Cancer Research (RTFCCR) funds patient-centered phase I–III interventional clinical trials that improve detection, treatment, implementation, and quality of life. Applications are managed in SmartSimple; LOIs are reviewed three times per year.
Eligibility criteria:
-
Applicant organization is an academic or not-for-profit institution (worldwide where oversight is feasible).
-
Projects are interventional clinical trials (Phase 1–3) with patient partner involvement in protocol design.
-
Pre-clinical validation considered only for applications focused on detecting and intervening in early cancer (pre-cancerous changes).
-
Agents may be generic (repurposed), registered for the indication, or academically developed.
-
Immunotherapy trials must be discussed with RTFCCR before submission.
-
Final selection depends on scientific review, strategic portfolio fit, and funds availability.
Funding details:
-
Supports phase I–III interventional trials; does not fund basic research, phase IV, or purely observational studies.
-
Pre-application grants are available to support patient partners contributing to application design.
-
Awards and payments are administered via SmartSimple; progress reporting occurs in-portal.
Deadline:
-
Upcoming LOI deadline: November 23, 2025.
-
Additional LOI review dates: March 9, 2026; May 29, 2026; November 23, 2026.
-
LOIs accepted on a rolling basis; invited full application deadlines are provided after LOI review.
Where to go for further information: